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are at present practically impossible to culture. By using simple
cyst puriﬁcation methods, we show that Giardia whole genome
sequencing of clinical stool samples is possible. Immunomagnetic
separation after sucrose gradient ﬂotation gave superior results
compared to sucrose gradient ﬂotation alone. The method
enables detailed analysis of a wide range of genes of interest for
genotyping, virulence and drug resistance.
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G. intestinalis, G. duodenalis) against metronidazole is increasingly
seen in clinical practice, but clinically relevant mechanisms of
resistance are largely unknown [1]. Many issues of Giardia viru-
lence and pathogenicity are also unresolved [2]. Further progress
in this ﬁeld is hampered by the difﬁculty of culturing clinical
samples [3]. Genotyping of Giardia for studies of epidemiology,Microbiol Infect 2015; 21: 192.e1–192.e3
nical Microbiology and Infection © 2014 European Society of Clinical Microbiology and Infect
p://dx.doi.org/10.1016/j.cmi.2014.08.014symptomatology, virulence and drug resistance has therefore
been limited topolymerase chain reaction (PCR) ampliﬁcation and
partial sequencing of one, or a few, speciﬁc genes [4,5].
Recently, genomes of three culturable isolates, representa-
tive of G. lamblia assemblages infective to humans (A1, A2 and
B), have been sequenced [6–8]. The aim of the present study
was to evaluate whether it is possible to obtain a satisfactory
coverage and depth with whole genome sequencing of cysts
puriﬁed directly from patients’ stool samples.
Giardia cyst puriﬁcation was performed in three clinical
samples, one assemblage A2 (sample 1) and two assemblage B
(sample 2 and 3), using 4 g of faeces from each. Samples were
washed by repeated centrifugation at 500 × g with dH2O until
the supernatant was clear. Then sucrose gradient ﬂotation
(SF) was done by placing the remaining pellet material on top
of a 1 M sucrose solution before centrifuging at 600 × g for
10 minutes. The supernatant was collected and went through
one repeated SF cycle before the remaining material above the
sucrose gradient was washed again, and half of it became the
SF fraction from which DNA was extracted (Fig. 1a). The
other half was further puriﬁed by immunomagnetic separation
(IMS) with magnetic beads coupled to antibodies against
Giardia cyst wall protein-1 (Waterborne Inc., New Orleans,
LA) (Fig. 1b). Cultured Giardia trophozoites (strain WB,
ATCC 50803) were included for reference and internal
control.
DNA was extracted using the Qiagen Stool Kit after ﬁve
freeze/thaw cycles and was measured using Qubit 2.0 (Life
Technologies, Grand Island, NY). Giardia genotype was deter-
mined by triosephosphate isomerase (tpi)-PCR and sequencing
[9]. DNA quality was assessed by Agilent 2100 BioAnalyzer
using the DNA 1000 and High Sensitivity DNA kit (Agilent
Technologies, Santa Clara, CA) and was sequenced on a SOLiD
5500xl system after per-protocol fragmentation and random
ampliﬁcation. LifeScope Genomic Analysis Software v.2.5.1 for
SOLiD Next-Generation Sequencing and the genomic.rese-
quencing.frag workﬂow were used for mapping the resulting
reads to the relevant Giardia reference genome: assemblage A1
(WB) [6], assemblage A2 (DH) [8] and B (GS) [7]. Mapped
sequences were analysed using the software packages SAMtools
(http://samtools.sourceforge.net/) and R (http://www.r-project.
org/) to evaluate coverage and depth of the genome as a
whole and in a selected set of three genes commonly used for
genotyping (tpi, glutamate dehydrogenase, β-giardin) [5], four
genes important in host–pathogen interactions (arginine deimi-
nase, ornithine carbamoyltransferase, fructose-bisphosphate
aldolase, enolase) [10] and seven metabolic genes involved in
metronidazole function (NADH oxidase, NADH ferredoxin
oxidoreductase, pyruvate ferredoxin oxidoreductase, thioredoxinious Diseases. Published by Elsevier Ltd. Open access under CC BY-NC-ND license.
FIG. 1. (a) Three Giardia cysts (ar-
row) after sucrose gradient ﬂotation.
Some faecal debris and probably fungi
are still present. (b) One Giardia cyst
(arrow) after immunomagnetic sepa-
ration. It is covered by magnetic
beads coupled to cyst wall protein.
Original magniﬁcation, 40×.
CMI Hanevik et al. Sequencing of Giardia lamblia 192.e2reductase, nitroreductase family protein, malate dehydrogenase,
nitroreductase Fd-NR2) [11].
The DNA extraction yields were low for all three clinical
samples. Levels of IMS puriﬁed samples were all below the Q-
bit measurement range (<0.01 ng/μL) (Table 1). Between seven
and ten ampliﬁcation cycles were used before sequencing.
Sequencing read lengths were between 25 and 75 bases.
Mapping data for the cultured control and puriﬁed clinical
samples are listed in Table 1. When mapped against their
matching reference genomes, reads from two out of three SF
puriﬁed clinical samples revealed a 1× genome coverage of
>87% and above 85% for all the clinical samples puriﬁed by IMS
after SF. The IMS-puriﬁed samples had the highest depth, with
36.5%, 63.7% and 82.5% of the genome covered 10×.
Evaluations of single gene coverages are shown in
Supplementary Tables S1 to S6. Within the IMS-puriﬁed sam-
ples, the 1× coverage of the complete length of the three
genotyping genes was above 87.7% in sample 1, 100% in sampleTABLE 1. Presequencing characteristics and sequence analysis resu
isolate
Cultured trophozoites (WB) Pa
Assemblage A1 A2
Reference genome used, isolate (genome) WB (AACB) DH
Puriﬁcation method Centrifugation only SF
Q-bit DNA quant (ng/μL) 12.3 < 0
DNA ampliﬁcation cycles 7 10
BioAnalyzer DNA quality OK No
Mean fragment size (bp) 281 267
Q-bit DNA quant (ng/μL) 0.026 0.1
Total no. of reads (1000×) 23 563 10
No. of reads mapped to reference (1000×) 21 203 1 1
Reads mapped to reference, % 90.0 11.
No. of genome bases covered 1× (1000×) 10 988 9 7
Genome covered to 1× depth (%) 98.0 91.
Genome covered to 5× depth (%) 97.3 51.
Genome covered to 10× depth (%) 97.2 14.
Mean depth per base 85.7 5.1
Min–max reads per base 0–1401 0–
SF, sucrose gradient ﬂotation; IMS, immunomagnetic separation.
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Open access under CC BY-NC-ND license.2 and above 99.3% in sample 3. The corresponding ﬁgures for
the SF-puriﬁed samples were between 11.5% and 100%. For the
host–pathogen interaction genes, we also found the IMS-
puriﬁed samples to cover over 99% of the complete gene se-
quences in samples 2 and 3, while sample 1 had a 1× coverage
of 89.2 and above. Likewise, in the metabolism gene set, we
found the complete genes to be covered 1× by 97.7% or more
in all samples. The 5× coverage was above 50% for sample 1,
above 98% for sample 2 and above 80% for sample 3.
By purifying Giardia cysts from clinical faecal samples, we
demonstrated that it is possible to achieve good coverage of the
Giardia genome as a whole and for genes of particular interest.
We also show that cyst puriﬁcation by sucrose ﬂotation alone
gives variable success, and that further puriﬁcation with IMS gives
better results, even with a very low amount of extracted DNA.
Coverage in sample 2 was good for both SF and IMS as a
result of a high number of cysts in the faeces. Sample 3 was
from a person with metronidazole refractory giardiasis andlts for three clinical Giardia isolates and one cultured reference
tient sample 1 Patient sample 2 Patient sample 3
B B
(AHGT) GS (ACGJ) GS (ACGJ)
SF + IMS SF SF + IMS SF SF + IMS
.01 < 0.01 1.40 < 0.01 1.41 < 0.01
8 10 10 8 8
t visible Not visible OK OK OK OK
262 280 269 288 292
54 0.141 0.059 0.259 0.145 0.211
612 2 245 21 362 16 792 26 660 7 009
70 1 279 4 365 8 387 181 2 147
0 57.0 20.4 49.9 0.7 30.6
84 10 281 10 485 10 553 6 155 10 313
4 96.0 87.2 87.8 51.2 85.8
5 79.1 82.7 85.0 1.9 79.3
4 36.5 75.9 82.5 0.1 63.7
7.4 18.4 35.1 1.1 12.8
95 0–128 0–2101 0–4145 0–3539 0–1109
nfectious Diseases. Published by Elsevier Ltd. CMI, 21 192.e1–192.e3
192.e3 Clinical Microbiology and Infection, Volume 21 Number 2, February 2015 CMIhad far fewer cysts. In SF-puriﬁed cysts, a variable amount of
faecal debris, of similar speciﬁc weight to Giardia cysts, re-
mains. This probably accounts for the large variability in the
number of mapped reads and the resulting low coverage in
some SF-puriﬁed samples. A sample with several Giardia ge-
notypes would pose a problem for the choice of reference
genome and the analysis, but it would also be a challenge for
conventional PCR, or any sequencing method. The sequencing
technique used here produces relatively short reads. Larger
structural genome changes therefore cannot be discovered.
The ampliﬁcation steps in the procedure may also induce
artefacts. Further optimization of cyst puriﬁcation and newer
sequencing methods with longer read lengths and no ampli-
ﬁcation steps are likely to improve these results considerably.
The successful genomewide sequencing directly from clinical
isolates of Giardia opens possibilities for correlations between
clinical disease, severity, susceptibility to antimicrobial drugs
and genetic composition of the parasite. It is likely that other
difﬁcult-to-culture intestinal microorganisms of clinical impor-
tance, such as cryptosporidium, could be puriﬁed and
sequenced in a similar fashion.Transparency declarationThis work was supported by the University of Bergen. All au-
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